Natasa Ristic1, Vladimir Ajdzanovic2, Milica Manojlovic-Stojanoski3, Jovana Maliković3, Gordana Uscebrka4, Zorica Markovic5, Verica Milosevic3. 1. Department of Cytology, Institute for Biological Research "Siniša Stanković", University of Belgrade, Belgrade, Serbia. Electronic address: negicn@ibiss.bg.ac.rs. 2. Department of Cytology, Institute for Biological Research "Siniša Stanković", University of Belgrade, Belgrade, Serbia. Electronic address: avlada@ibiss.bg.ac.rs. 3. Department of Cytology, Institute for Biological Research "Siniša Stanković", University of Belgrade, Belgrade, Serbia. 4. Department of Veterinary Medicine, Faculty of Agriculture, University of Novi Sad, Novi Sad, Serbia. 5. Clinical Centre "Dr Dragiša Mišović", Belgrade, Serbia.
Pituitary mammotrophs, i.e. prolactin(PRL) producing cells, in rats are distributed throughout the anterior-ventral part as well as in the areas near the gland pars intermedia (1). Classification of mammotrophs takes secretory granule size as a key criterion and accordingly three types of these cells are identified (1,2). PRL is a pulsatile secreted polypeptide hormone, functionally entwined with ovulation, pregnancy or nursing and characterized by a significant, age-related rise in females (1,3,4). Also, the number of female mammotrophs and their DNA content increase with ageing (5,6). Generally, the intensified PRL release with age is partly due to dysfunction of the dopaminergic mechanism in the hypothalamus (7). Studies in postmenopausal subjects have confirmed these secretory changes as far-reaching, since PRL levels do not decrease in that period of life (8).Premature menopause, linked with estrogen deficiency and infertility in young women, can develop spontaneously or may be caused by iatrogenic factors (9). A whole range of profound symptoms such as hot flashes, bone deterioration, decreased libido, cardiovascular issues and depression are included into its manifestation (9,10). When it comes to the mammotroph function in premature menopausal females, it was found long ago that PRL levels remain within normal range, while the pulsatility of secretion flattens (11). Estrogen replacement therapy is a common therapeutic approach to treat menopausal symptoms, with confirmed effectiveness in osteoporosis treatment (12), but due to possible adverse effects (breast or endometrial cancer, thromboembolic events) careful selection of dosage and duration of use are advised (13,15).Literature data have already pointed out that estradiol potently influences mammotroph differentiation, function and proliferation in vitro (16), while its effects in prematurely menopausal females remain insufficiently elaborated. Since estradiol application in menopausal subjects may change the histological parameters of pituitary mammotrophs and PRL secretion, our aim was to explain the phenomenology of potential estradiol-caused changes in ovariectomized adult female rats using modern histological and biochemical methodologies. Thus, in our model reflecting premature natural/iatrogenic menopause, we investigated the immunohistomorphometric characteristics of pituitary mammotrophs, using a design-based stereological approach, as well as their secretory ability, by measuring the optical density (OD) of immunostaining and the circulating PRL levels (17,18).
Materials and Methods
Experimental design
In this experimental study, 21 female Wistar rats 12-weeks old (with the average body mass about 290 g) were housed in the experimental animal unit of the Institute for Biological Research "Siniša Stanković" and maintained under standard laboratory conditions (room temperature at 22 ± 2˚C and a 12 hour light: 12 hour dark cycle). Food and water were available ad libitum. The rats were divided into three groups (n=7). Females from two groups were bilaterally ovariectomized (OVX) under nembutal anesthesia (25 mg/ml distilled water). One month after ovariectomy, the first OVX group was treated through an intraperitoneal (i.p.) injection with 0.625 mg/kg b.m. of estradiol dipropionate (Oestradiol, Galenika a.d., Beograd, Srbija, OVX+E) per day for 4 weeks. The estradiol dose was selected based upon a previous work reporting its usage in clinical practice to treat postmenopausal women (19). Female rats in the second group represented long-term OVX controls injected with sterile olive oil for 4 weeks. The third group consisted of non-ovariectomized females injected with sterile olive oil (C) for 4 weeks. All females were sacrificed under ether anesthesia (ether ad narcosis Ph. Iug. III., Lek, Ljubljana, Slovenia) 24 hours after the last treatment.All animal procedures were adjusted to the European Communities Council Directive (86/609/EEC) and were approved by the Ethical Committee for the Use of Laboratory Animals of the Institute for Biological Research "Siniša Stanković", University of Belgrade, Serbia (Approval No. 2-12/13).
Light microscopy and immunocytochemistry
After decapitation, pituitary glands were excised, weighed and fixed in Bouin’s solution for 48 hours at room temperature. After dehydration in a series of increasing ethanol gradient, the pituitaries were enlightened in xylene and embedded in paraplast. Series of seven sections (5 mm) of the pituitary cut through three tissue levels (dorsal, middle and ventral portion) of the pars distalis were used for immunostaining. Mammotrophs were identified by immunohistochemistry using the peroxidase-antiperoxidase (PAP) method as previously described in detail (4).
Morphometry
Image acquisition, morphometric assessment and digital imaging were performed using a light microscope (Olympus BX-51, Olympus, Japan) equipped with a microcator (Heidenhain MT1201, Heidenhain, USA) to control movements in the z-direction (0.2 µm accuracy), a motorized stage (Prior, Prior Scientifi Inc., USA) for stepwise displacement in the x-y direction (1 µm accuracy), and a CCD video camera (PixeLink, PixeLINK, Canada) connected to a 19” LCD computer monitor (Dell 1907FPc, Dell Inc., Round Rock, TX, USA). Image acquisition and stage movement were controlled by the newCAST stereological software package [Visiopharm Integrator System (VIS), version 2.12.1.0, Visiopharm, Denmark] running on a personal computer.Volume density (VV) represents the percentage
of immunoreactive mammotrophs in the
pituitary glands of experimental and control
female rats. Two sections from the dorsal, three
from the middle and two from the ventral part
of rat pituitary glands were analyzed (the same
sections were used in the subsequent estimation
of number of mammotrophs per unit area-mm2
and cell volume determination). The counting
area was defined using a mask tool. The new
CAST software generated an interactive test
grid, characterized by uniformly spaced test
points for histomorphometric assessment. Test
points hitting the immunoreactive mammotrophs
and the uncolored phase of adenohypophysis
were determined. VVs of mammotrophs were
calculated as the ratio of the number of points
hitting immunoreactive mammotrophs with
nuclei divided by the number of points hitting
the uncolored phase of adenohypophysis:VV (%)=Pp/Pt×100.Pp=points hitting the immunoreactive
mammotrophs with nuclei, Pt=points of the
test system hitting the uncolored phase of
adenohypophysis.VV of mammotrophs was calculated for each
analyzed section. Then, the average value for
seven analyzed sections was calculated and it
represents the VV of mammotrophs in a pituitary
gland per animal.The number of mammotrophs per mm2 was
also calculated. In the first step, the areas of
analyzed sections were determined by the
Measure Properties option (Polygon area) and
then, by simple point counting, the number of
immunoreactive mammotrophs was estimated.
Additionally, the number of mammotrophs was
expressed per unit area (mm2). The single cell
volume (μm3) of mammotrophs was measured
using the rotator tool.
Pituitary mammotrophs optical density measurements
The Windows based ImageJ program (Image J,
version 1.50f) was used for the analysis. Namely,
30 unbiasedly captured images (the microscopic
tool has already been described: 2088×1550
pixels, ×63 objective magnification) per
mammotroph specific-immunostained pituitary
per animal were analyzed. Initially, the spectral
deconvolution method of 3,3′-diaminobenzidine
tetrahydrochloride (DAB)/Hematoxylin color
spectra was performed, using optimized OD
vectors of the color deconvolution plug-in for
adequate separation of the DAB color spectra.
To determine the OD for the red, green and blue
(RGB) channel of Hematoxylin and DAB, we
followed the protocol as previously described
by Ruifrok and Johnston (20) and Varghese et
al. (21). Since the OD is proportional to the
concentration of the stain in mammotrophs, the
amount of stain present is a factor determining the OD at a wave length specific to the stain,
according to the formula:OD=-log10 (IC/I0.C),where I represents the transmitted light, IC is the intensity of detected light after passing
through a specimen and I0.C refers to the intensity
of light entering the specimen.
Hormonal analysis
Blood was collected from the trunk and separated sera samples of all animals were stored at the same time at -70˚C until assayed. Serum concentrations of PRL in control and experimental female rats were measured by the non-isotopic two-step assay (Delfia) method (hPRL-Delfia kits, LKB, Turku, Finland).
Statistical analysis
Morphometric and hormonal data obtained for each group of female rats were averaged and SD was calculated with STATISTICA ®version 7.0 (StatSoft Inc., USA). One-way analysis of variance (ANOVA), followed by the multiple range test of Tukay (honest significant difference) HSD was used for comparison of the differences between groups. A probability value of 5% or less was considered statistically significant.
Results
The values of body mass, and absolute and relative pituitary weights are shown in Table 1. OVX caused significant (P<0.05) increase in the body mass of adult female rats by 16% in comparison with non-ovariectomized females, while absolute and relative pituitary weights were not significantly changed. In OVX+E females, body mass was significantly (P<0.05) decreased by 32% in comparison with the OVX group. Absolute and relative pituitary weights in the OVX+E group were 2.6-fold (P<0.05) and 3.4-fold (P<0.05) higher than in the OVX group, respectively.In control, pituitary glands’ mammotrophs
were spread throughout the pars distalis. These
cells were oval or polygonal in shape and strong
immunoreactivity was pronounced in their
cytoplasm. After ovariectomy, mammotrophs
were irregularly shaped and decreased
intensity of immunostaining was noticed.
In OVX+E females, the mammotrophs were
irregularly shaped, with dark colored secretory
granules (Fig .1). The quantitative analysis of
mammotrophs showed that ovariectomy caused
significant (P<0.05) decrease of their OD, VV and
number per mm2 by 29, 27 and 34%, respectively,
in comparison with control non-ovariectomized
females. In the OVX+E group, significant
(P<0.05) increases in OD, cell volume, VV
and number of mammotrophs per mm2 by 181,
15%, 5.8-fold and 5.2-fold, respectively, were
observed when compared to OVX animals
(Figes.2, 3). The serum concentration of PRL
in OVX females was significantly (P<0.05)
decreased by 14% in comparison with nonovariectomized
controls. In OVX females,
estradiol treatment significantly (P<0.05)
increased PRL concentration in serum by 53%
compared to the OVX control (Fig .3).
Fig.1
Immunopositive mammotrophs in pars distalis of the
pituitary gland from C, OVX and OVX+E adult female rats
(magnification: ×63, bar=16 μm).
C; Non-ovariectomized, OVX; Ovariectomized, and OVX+E;
Estradiol-treated ovariectomized.
Fig.2
Morphometric parameters of pituitary mammotrophs. A.
Vv (%), B. Number per mm2, and C. Volume (μm3) in C, OVX and
OVX+E adult female rats, results are given as means ± SD (n=7).
C; Non-ovariectomized, OVX; Ovariectomized, OVX+E; Estradioltreated
ovariectomized, a; P<0.05 vs. C, and b; P<0.05 vs. OVX.
Fig.3
Secretory ability of pituitary mammotrophs. A. OD of pituitary mammotrophs and B. Serum PRL levels (mU/L) in C, OVX and OVX+E adult female rats, results are given as means ± SD (n=7).
OD; Optical density, PRL; Prolactin, C; Non-ovariectomized, OVX; Ovariectomized, OVX+E; Estradiol-treated ovariectomized, a; P<0.05 vs. C, and b; P<0.05 vs. OVX.
The body mass and absolute and relative pituitary weights among C, OVX and OVX+E adult female ratsResults are given as means ± SD (n=7).C; Non-ovariectomized, OVX; Ovariectomized, OVX+E; Estradiol-treated ovariectomized, a; P<0.05 vs. C , b; P<0.05 vs. OVX.Immunopositive mammotrophs in pars distalis of the
pituitary gland from C, OVX and OVX+E adult female rats
(magnification: ×63, bar=16 μm).C; Non-ovariectomized, OVX; Ovariectomized, and OVX+E;
Estradiol-treated ovariectomized.Morphometric parameters of pituitary mammotrophs. A.
Vv (%), B. Number per mm2, and C. Volume (μm3) in C, OVX and
OVX+E adult female rats, results are given as means ± SD (n=7).
C; Non-ovariectomized, OVX; Ovariectomized, OVX+E; Estradioltreated
ovariectomized, a; P<0.05 vs. C, and b; P<0.05 vs. OVX.Secretory ability of pituitary mammotrophs. A. OD of pituitary mammotrophs and B. Serum PRL levels (mU/L) in C, OVX and OVX+E adult female rats, results are given as means ± SD (n=7).OD; Optical density, PRL; Prolactin, C; Non-ovariectomized, OVX; Ovariectomized, OVX+E; Estradiol-treated ovariectomized, a; P<0.05 vs. C, and b; P<0.05 vs. OVX.
Discussion
Ovariectomized adult female rats, reflecting premature natural/iatrogenic menopause (17,18), were used in our experiment to investigate the histological parameters and secretory ability of their pituitary mammotrophs upon estradiol application. In brief, estradiol caused a significant increase in the number and size of mammotrophs, and positively affected the synthesis and secretion of PRL, based on OD and serum PRL levels determination.Firstly, we have provided evidence that hypoestrogenism, caused by ovariectomy, leads to an increase in body mass. Kurachi et al. (22) observed increased body mass upon ovariectomy accompanied by adipocyte hypertrophy. Estrogen withdrawal provoked by ovariectomy may influence body mass regulation at the central level, given the fact that estrogen receptors (ERs) α and β are found in the hypothalamic areas responsible for body mass regulation. In ERα deficient mice, a significant adipose tissue gain is observed, indicating a role of estrogen in the central regulation of body mass (23). Increases in the hypothalamic neuropeptide Y (NPY) expression (24) and decreases in hypothalamic corticotrophin- releasing hormone (CRH) immunoreactivity (25), both of which may promote hyperphagia, have also been established after ovariectomy. These changes in hypothalamic NPY and CRH could be explained by central leptin insensitivity associated with increased body mass in estrogen- deficient rats (26). Herein, chronic treatment of ovariectomized female rats with estradiol caused a significant body mass reduction in comparison to ovariectomy alone. Estrogen replacement therapy has already been shown to decrease body mass and food intake by the suppression of NPY or galanin- like peptidergic systems in the hypothalamic arcuate nucleus or medial preoptic area (27,28). Furthermore, estradiol treatment normalized all the changes in energy balance induced by ovariectomy, indicating that estrogen deficiency is responsible for energy imbalance (26).The further course of our study implied the
examination of histological parameters of
pituitary mammotrophs together with PRL levels
measurement after ovariectomy and subsequent
estradiol treatment. Mammotrophs generally
show morphological, functional and physiological
heterogeneity, the characteristics which are
closely associated with estrogenic environment
(29). Bearing in mind that the mammotroph
cell population shows a remarkable ability
to numerically change in response to various
physiological and experimental conditions (30),
their decreased VV and number per mm2 in the
hypoestrogenic milieu, caused by ovariectomy
in our experiment, could be explained by the
transdifferentiation of mammotrophs into
gonadotropic cells. Transdifferentiation within the
pituitary hormone-producing cell population is
suggested to be an important event that aimed at
providing homeostasis during specific physiological
challenges (31). In line with the observed decrease
in mammotroph immunohistomorphometric parameters and their potential transdifferentiation,
serum concentrations of PRL expectedly fell
in our study. Finally, the absolute and relative
pituitary weights in our experimental set-up
remain unchanged, which can also be supported
by the gonadotropic cell population rise after
transdifferentiation and some partially achieved
equilibrium in this respect.Chronic treatment of our ovariectomized
female rats by estradiol led to an increase in OD
values, individual cell volume, VV and number
of mammotrophs per mm2, which was followed
by increased serum concentrations of PRL. The
stimulatory effect of estradiol observed could be
explained by the events at both the hypothalamic
and the pituitary levels. Namely, at the level of
hypothalamus, estrogen facilitates the release
of hypophysiotrophic stimulatory factors (32),
acting through widely present ERs in numerous
hypothalamic neuronal populations (33). At the
pituitary level, estrogen mediates the action of
locally produced growth factors like insulin growth
factor-1 (IGF-1), fibroblastic growth factor-2
(FGF-2) and epidermal growth factor (EGF)
(34-36). In line with this, the increased values of
stereological parameters (mammotroph volume
and VV) observed are in coherence with promoted
mammotroph cell synthetic activity as well as
proliferation due to increased local production of
FGF-2 in an estrogen environment (37). Based
on the herein observed intensive mammotroph
immunostaining/high OD, increased cell volume
and elevated PRL levels, processes of PRL
synthesis and secretion obviously remain under the
stimulatory estradiol influence, as already reported
(16). To note, PRL gene expression is enhanced
through a mechanism that is mediated directly by
the anterior pituitary ERs (38). Finally, estrogen
promotes the mammotroph cell proliferation
and early development of their hyperplasia by
inducing Pit-1 transcription factor expression,
which is considered the strongest predictor of
prolactinomas (37, 39).
Conclusion
The main contribution of our results to the
investigation field is reflected in the detected ability
of mammotrophs to change their appearance, size
and secretion according to the varying estrogen
environment, like ovariectomy and ovariectomy
followed with estradiol treatment. By applying a
modern histological approach, the mammotroph
cell volume, VV, number of mammotrophs per mm2
and their OD were estimated, providing insight
into the dynamics of mammotroph cell population
in this respect. From the biomedical point of view,
these quantitative and analytical histology based
information could be relevant as an indicator of
possible prolactinome or some other PRL-related
disorder development upon estradiol application
to premature menopausal subjects.
Table 1
The body mass and absolute and relative pituitary weights among C, OVX and OVX+E adult female rats
Group
Body mass (g)
Absolute pituitary weight (mg)
Relative pituitary weight (mg%)
C
288 ± 18
14.2 ± 1.4
5.0 ± 0.7
OVX
334 ± 40a
16.5 ± 3.4
5.6 ± 1.3
OVX+E
227 ± 39b
42.8 ± 6.5b
18.8 ± 5.3b
Results are given as means ± SD (n=7).
C; Non-ovariectomized, OVX; Ovariectomized, OVX+E; Estradiol-treated ovariectomized, a; P<0.05 vs. C , b; P<0.05 vs. OVX.
Authors: Ana Lucía De Paul; Silvina Gutiérrez; María E Sabatino; Jorge H Mukdsi; Claudia M Palmeri; Marta Soaje; Juan P Petiti; Alicia I Torres Journal: Exp Physiol Date: 2011-02 Impact factor: 2.969